Fighting the Zika virus with the power of supercomputing

Rutgers is taking a leading role in an IBM-sponsored World Community Grid project that will use supercomputing power to identify potential drug candidates to cure the Zika virus. The project, known as OpenZika, employs a global team of scientists who will perform "virtual" experiments in a search of treatments for the fast-spreading virus that the World Health Organization has declared a global public health emergency.

OpenZika will screen current drugs and millions of drug-like compounds from existing databases against models of Zika protein structures (and also against structures of proteins from related viruses, including West Nile Virus and Dengue). These computational results will be shared quickly with the research community and general public, with compounds showing the most promise then tested in laboratory settings.

"Instead of having to wait a number of years, even decades potentially, to test all these compounds in order to find a few that could form the basis of antiviral drugs to cure Zika, we will perform these initial tests in a matter of months, just by using idle computing power that would otherwise go to waste," says Alex Perryman, a research teaching specialist at Rutgers' New Jersey Medical School, in Professor Joel Freundlich's lab. Perryman was selected as co-principal investigator of the OpenZika project, while Freundlich serves as a key consultant.

IBM created World Community Grid in 2004 to address researchers' critical need for supercomputing power. Partially hosted on IBM's SoftLayer cloud technology, World Community Grid provides massive amounts of supercomputing power to scientists for free by harnessing the unused computing power of volunteers' computers and Android devices.

IBM and the scientific team are seeking volunteers with a computer or Android device to join the OpenZika project. The volunteers, who can sign up on the World Community Grid website, need not have a particular expertise. Nor are there financial obligations or time commitments. All participants need to do is run an app on their Windows, Mac, Linux or Android devices that automatically performs virtual experiments whenever their machines are idle.

More than three million computers and mobile devices used by nearly 750,000 people and 470 institutions across 80 countries have combined to create World Community Grid, which makes it one of the largest supercomputers on the planet. These volunteers have contributed supercomputing power for more than two dozen World Community Grid projects over the past 11 years, at an estimated value of more than $500 million.

Rutgers' Perryman has had deep experience working with IBM's World Community Grid. From 2007 to 2013, he managed and performed the day-to-day duties required for FightAIDS@Home, the first biomedical computing project on World Community Grid. In 2011, Perryman designed, developed and ran the grid's Global Online Fight Against Malaria (GO FAM) project, which has resulted in identifying promising tool compounds for treating malaria and drug-resistant tuberculosis.

In less than two years, GO FAM volunteers on the grid performed more than a billion docking jobs, which, Perryman estimates, would have taken at least 100 years using the computer capacity found at most universities. The Freundlich lab has leveraged GO FAM data against tuberculosis drug targets, along with novel machine learning techniques they have developed, to seed novel therapeutic strategies.

In addition to Perryman's GO FAM project, World Community Grid has helped researchers identify new potential treatments for childhood cancer, test materials for more efficient solar cells, and study how nanotechnology can filter water more efficiently.

For the OpenZika project IBM is working with an international team of researchers, led by Federal University of Goias in Brazil; with scientists from the Oswaldo Cruz Foundation (Fiocruz) in Brazil; Rutgers University's New Jersey Medical School (NJMS); and the University of California, San Diego (UCSD). Carolina Horta Andrade, professor at Federal University of Goias, is the principal investigator. Joining Perryman as co-PI is Sean Ekins, CEO, Collaborations Pharmaceuticals.

Volunteers can support the OpenZika search for a cure by joining World Community Grid. IBM also invites researchers to submit research project proposals to receive this free resource. For more information about IBM's philanthropic efforts, visit http://www.citizenIBM.com.

Most Popular Now

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

Pfizer reaches a global agreement with AbbVie

Pfizer Inc. (NYSE:PFE) has signed licensing agreements with AbbVie, resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar. Under ...

FDA grants breakthrough device designation to arti…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thrombo...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

GSK reaches agreement to acquire TESARO, an oncolo…

GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...